These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 37774953)

  • 1. Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration.
    Chacin Ruiz EA; Swindle-Reilly KE; Ford Versypt AN
    J Control Release; 2023 Nov; 363():464-483. PubMed ID: 37774953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration.
    Luaces-Rodríguez A; Mondelo-García C; Zarra-Ferro I; González-Barcia M; Aguiar P; Fernández-Ferreiro A; Otero-Espinar FJ
    Int J Pharm; 2020 Jan; 573():118767. PubMed ID: 31669558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous Release of Aflibercept and Dexamethasone from an Ocular Drug Delivery System.
    Rudeen KM; Liu W; Mieler WF; Kang-Mieler JJ
    Curr Eye Res; 2022 Jul; 47(7):1034-1042. PubMed ID: 35343355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
    Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD).
    Sarkar A; Junnuthula V; Dyawanapelly S
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal hydrogels for sustained release of therapeutic proteins.
    Ilochonwu BC; Urtti A; Hennink WE; Vermonden T
    J Control Release; 2020 Oct; 326():419-441. PubMed ID: 32717302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies.
    Alshaikh RA; Waeber C; Ryan KB
    Adv Drug Deliv Rev; 2022 Aug; 187():114342. PubMed ID: 35569559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema.
    Wong CW; Wong TT
    Br J Ophthalmol; 2019 Oct; 103(10):1356-1360. PubMed ID: 31040133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-based drug delivery systems in the treatment of wet age-related macular degeneration.
    Du JD; Fong WK; Caliph S; Boyd BJ
    Drug Deliv Transl Res; 2016 Dec; 6(6):781-792. PubMed ID: 27194165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Khanani AM; Callanan D; Dreyer R; Chen S; Howard JG; Hopkins JJ; Lin CY; Lorenz-Candlin M; Makadia S; Patel S; Tam T; Gune S;
    Ophthalmol Retina; 2021 Aug; 5(8):775-787. PubMed ID: 33217618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.
    Bisht R; Jaiswal JK; Rupenthal ID
    Med Hypotheses; 2017 Jun; 103():5-9. PubMed ID: 28571808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal injectable hydrogel rods with long-acting bevacizumab delivery to the retina.
    Lee S; Hong HK; Song JS; Jeong SI; Chung JY; Woo SJ; Park KD
    Acta Biomater; 2023 Nov; 171():273-288. PubMed ID: 37739248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanodelivery of Resveratrol-Loaded PLGA Nanoparticles for Age-Related Macular Degeneration.
    Bhatt P; Fnu G; Bhatia D; Shahid A; Sutariya V
    AAPS PharmSciTech; 2020 Oct; 21(8):291. PubMed ID: 33085055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and treatment of age-related macular degeneration: an update for pharmacists.
    Marshall LL; Roach JM
    Consult Pharm; 2013 Nov; 28(11):723-37. PubMed ID: 24217192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chitosan-Polycaprolactone Core-Shell Microparticles for Sustained Delivery of Bevacizumab.
    Jiang P; Jacobs KM; Ohr MP; Swindle-Reilly KE
    Mol Pharm; 2020 Jul; 17(7):2570-2584. PubMed ID: 32484677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor.
    Prahs P; Brandl C; Helbig H; Volz C
    Rom J Ophthalmol; 2023; 67(3):260-266. PubMed ID: 37876508
    [No Abstract]   [Full Text] [Related]  

  • 17. Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration.
    Papadopoulos Z
    Eur J Ophthalmol; 2019 Jul; 29(4):368-378. PubMed ID: 30813810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An anti-angiogenic reverse thermal gel as a drug-delivery system for age-related wet macular degeneration.
    Park D; Shah V; Rauck BM; Friberg TR; Wang Y
    Macromol Biosci; 2013 Apr; 13(4):464-9. PubMed ID: 23316011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
    Yuzawa M; Fujita K; Wittrup-Jensen KU; Norenberg C; Zeitz O; Adachi K; Wang EC; Heier J; Kaiser P; Chong V; Korobelnik JF
    Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting formulation strategies for protein and peptide delivery in the treatment of PSED.
    Garkal A; Bangar P; Rajput A; Pingale P; Dhas N; Sami A; Mathur K; Joshi S; Dhuri S; Parikh D; Mutalik S; Mehta T
    J Control Release; 2022 Oct; 350():538-568. PubMed ID: 36030993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.